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Introduction
Type 1 diabetes mellitus (T1DM) is a devastating chronic metabolic 
disease whose incidence has been rising at alarming rates during the last 
decade [1]. T1DM pathophysiology has been clearly related to an innate 
immune system defect resulting in a loss of self-tolerance, leading to 
the destruction of pancreatic β-cells by self-reactive-T-lymphocytes 
[2]. Standard T1DM patients’ care strategies are based on the ongoing 
monitoring of food intake and continuous insulin prophylaxis. 
Nevertheless, endogenous insulin production and secretion are 
highly sensitive to minute-by-minute changes in blood glucose levels. 
Exogenous insulin injections thus do not represent a definitive cure 
for T1DM since they cannot mimic precise β-cell glucose homeostasis 
regulation. It must be stated that, even when being treated, T1DM 
patients develop severe long-term complications which clearly reduce 
their life-expectancy [3,4].  
Around 1,300 T1DM patients receive pancreas or β-pancreatic 
islet transplants from cadaveric donors each year in the USA as an 
alternative to insulin administration [5]. Around 80% of transplant 
recipients can become insulin injection free for a five-year period 
[6,7], thereby indicating that a cure for T1DM is possible through 
β-cell mass replenishment; however, the demand for organs exceeds 
their availability [8]. Transplanted patients have to undergo life-long 
nonspecific immunosuppressive regimens to avoid transplanted organs 
becoming rejected and thus hindering this therapy’s widespread use 
[9]. Such difficulties have led researchers to search for other sources of 
glucose-responsive insulin-producing cells; strategies based on different 
types of stem cell seem to be the most promising ones to date [10].       
Mesenchymal Stem Cells for Regenerating Pancreatic 
β-Cell Mass
The main challenge for successful stem cell therapy to treat 
T1DM lies in producing functional β-cells and overcoming the 
autoimmune response. In theory, β-cell mass and function could be 
preserved and/or restored in at least three different ways: replacing 
damaged β-cells by direct stem cell differentiation, modifying the 
pancreatic microenvironment allowing endogenous β-cell regeneration 
and abrogating the autoimmune response to β-cells. Multipotent 
mesenchymal stromal cells (also referred to as mesenchymal stem cells 
-MSCs), a heterogeneous adult stem cell population, seems to represent 
an ideal tool, since they can be easily isolated from bone-marrow and 
other mesenchymal tissue, like adipose tissue, dental pulp, placenta, 
Wharton’s jelly and umbilical cord, and rapidly expanded ex vivo 
[11,12]. MSCs are hypo-immunogenic, allowing allogeneic transplant 
without histocompatibility or recipient conditioning being required 
[13]. When MSCs are systemically administered they can selectively 
migrate and engraft in damaged tissue [14] and differentiate into 
insulin-producing cells [15,16]. As immunomodulatory cells, MSCs 
can limit inflammation in damaged tissue [17], produce a broad range 
of trophic factors protecting parenchymal cells from dying by apoptosis 
and promote the proliferation and differentiation of endogenous 
precursors [18]. MSCs have been transplanted into over 1,000 human 
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patients suffering different diseases, providing beneficial effects without 
inducing major toxicity [19-21].   
Replacing pancreatic β-cells by direct differentiation
One approach to produce more β-cells has involved differentiating 
MSCs into functional β-cells. Hisanaga et al., have shown that a simple 
protocol can induce murine bone marrow-derived MSC differentiation 
into insulin-secreting cells [22]; the differentiated cells contained 
insulin-secretory granules and secreted mature insulin after glucose 
stimulation. Such cells reduced blood glucose levels when they were 
transplanted into diabetic mice [22]. Zhang et al., have demonstrated 
that human bone marrow-derived MSCs could differentiate into 
pancreatic islet-like cell clusters when following a more complex four-
step induction protocol [23]. Differentiated cells have expressed a 
broad pancreatic β-cell genetic profile, released high levels of insulin 
in response to glucose stimulation in vitro and reduced blood glucose 
levels when transplanted to streptozotocin (STZ)-induced diabetic 
mice [23].   
Other studies have proved that human adipose-derived MSCs 
have been able to adopt a pancreatic endocrine cell phenotype in 
vitro [24,25]; differentiated cells co-expressing insulin, glucagon and 
somatostatin reduced blood glucose levels within two weeks when they 
were transplanted into STZ-induced diabetic mice [24,25]. Similar 
results have been obtained with MSCs isolated from dental pulp [26], 
placenta [27], Wharton’s jelly [28] and umbilical cord [29], suggesting 
that such therapeutic effect could be a common property for any type 
of MSCs. 
Some other reports have suggested that MSC differentiation 
into insulin-secreting cells could also be achieved in vivo [15,30,31]; 
transplanting undifferentiated bone marrow-derived MSCs into 
diabetic mice in these studies increased insulin levels and reduced 
hyperglycaemia. The authors found that some transplanted cells homed 
to pancreatic injury sites when analysing receptor mouse pancreatic 
tissue and that they differentiated into insulin-positive cells [15,30,31]. 
However, such cell lineage switch has still to be confirmed, since several 
other laboratories have reported that MSCs infused into diabetic mice 
lowered blood glucose level and increased β-cell mass but they could 
not differentiate into β-cells [32-34].  
Furthermore, while proof of concept has demonstrated that MSCs 
can differentiate into insulin-secreting cells (at least in vitro), such an 
approach is limited by an inability to achieve a fully-differentiated β-cell 
phenotype, the relatively low amount of insulin secreted in vivo and 
inefficacy in rapidly adapting to day-to-day physiological requirements. 
The scientific community is thus still searching for a well-defined and 
reproducible condition enabling this target to be achieved (i.e. to 
provide a clinically-relevant β-cell mass compatible with transplants in 
humans). 
Modifying the pancreatic microenvironment to allow 
endogenous regeneration of pancreatic β-cells
It is well-known that β-cell mass increases markedly during 
development and can also proliferate postnatally in response to 
situations involving increased metabolic demand, such as obesity and 
pregnancy [35]. Significant regeneration of pancreatic tissue, including 
β-cells, has also been shown in adult mice and rats following 70% 
pancreatectomy [36,37]. 
Several studies have shown that existing β-cells’ self-duplication 
and pancreatic ductal cell differentiation are the main mechanisms by 
which pancreatic β-cells could be replenished in rodents and humans 
[36,38,39]. Thus, stimulating β-cell replication or local precursor 
differentiation could provide a promising alternative by which diabetic 
patients’ β-cell mass could become restored. 
It is well-known that MSCs secrete a broad range of bioactive 
growth factors in their vicinity (i.e. VEGF, bFGF, IGF, HGF and EGF) 
[18]. Therefore, MSCs could provide trophic support for injured 
tissue by modifying the microenvironment to induce local precursor 
proliferation and differentiation, improve damaged tissue irrigation 
and prevent parenchymal cell apoptosis [18,40]. Hess et al., have shown 
that transplantation of bone marrow-derived cells has increased insulin 
levels in diabetic mice and reduced their hyperglycaemia [41]. A 
careful histological analysis of these animals’ pancreases has shown that 
transplanted cells homed to the pancreatic injury site and promoted 
endogenous pancreatic regeneration, probably by secreting trophic 
factors [41]. These results have also been replicated in another study 
showing that newly-produced β-cells were in close vicinity to donor 
MSCs, suggesting that the cells so administered were involved in 
pancreatic progenitor cell proliferation and differentiation [42]. 
Our group has recently reported that intravenous injection of bone 
marrow-derived MSCs into diabetic mice has increased EGF plasmatic 
and pancreatic levels [33]. It has been reported that transgenic 
expression of EGF in the pancreas enhances β-cell proliferation and 
differentiation [43] and combined EGF and gastrin treatment has 
increased β-cell mass in diabetic rodents due to neogenesis from 
pancreatic duct cells [44,45]. 
Adipose-derived MSCs represent a very promising approach 
to diabetes since they are endowed with a large number of bioactive 
mediators, such as leptin, adiponectin and visfastin, which are known to 
regulate glucose homeostasis [46]. The secretion of the aforementioned 
growth factors could thus create a tissue microenvironment assisting 
endogenous β-cell regeneration and damaged islet revascularisation. 
However, most work to date has been carried out on rodents and islet 
architecture and niches are highly variable among different species [47]; 
thus, whether this could happen in humans remains unknown.
β-cell regeneration in humans has been suggested by observing 
residual β-cells in T1DM patients after onset [48] or even many years 
after diagnosis [49]; nevertheless, it remains unclear whether residual 
β-cells or the remaining endogenous precursors could be stimulated to 
a mass great enough to control glycaemia.  
Abrogating autoimmunity to pancreatic β-cells
Although the circumstances initiating T1DM have not been fully 
understood, growing evidence has shown the deregulation of innate 
and adaptive immune system components [50]. It has been shown that 
diabetes develops by dendritic cell and macrophage invasion of the 
pancreas, followed by CD4 and CD8 T-lymphocyte, natural killer (NK) 
cell and B-lymphocyte infiltration [50]. β-cell death during the course 
of inflammation is probably mediated by direct contact with activated 
macrophages and self-reactive T-lymphocytes and by exposure to 
soluble mediators secreted by these cells, including pro-inflammatory 
cytokines, nitric oxide and oxygen free radicals [51]. 
Following the identification of the disease’s autoimmune aetiology, 
several immunosuppressive agents have been evaluated for preventing 
and/or reverting pancreatic β-cell destruction (reviewed by Waldron-
Lynch et al. [52]). Such studies have shown that some patients 
experienced short periods of normoglycaemia without insulin treatment 
[52]; nevertheless, immunosuppressive drugs’ chronic toxicity, a loss of 
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metabolic benefit after the withdrawal of immunosuppressive agents 
and a failure to induce a tolerant state have limited such therapies’ 
routine use [53].   
MSCs may thus prove to be useful in treating autoimmune 
diseases, such as T1DM, owing to their immunosuppressive and 
anti-inflammatory properties which could promote immunological 
tolerance [33,54]. MSCs have a wide range of immunomodulatory 
features as they can secrete anti-inflammatory cytokines and form cell-
to-cell inhibitory interactions [54,55]; they can also affect dendritic cell 
function by inhibiting monocyte precursor differentiation [56]. MSCs 
thus indirectly limit NK and T-cell expansion and cytotoxic activity and 
also promote the appearance of regulatory T-lymphocytes, inducing 
antigen-specific tolerance [57]. 
Some studies have shown that injecting MSCs into diabetic 
rodents has successfully returned plasma glucose values to normal 
levels and increased β-cell mass [33,58-61]; they have also shown that 
MSCs have significantly suppressed β-cell specific T-cell proliferation 
in the pancreas and increased pancreatic regulatory T-cell levels. 
Endogenous β-cell regeneration may thus be attributable to MSC 
immunomodulatory properties, which could protect newly-formed 
β-cells from destruction by T-lymphocytes, thereby re-establishing 
peripheral tolerance toward β-cells.
Regarding MSC ability to migrate to damaged tissue [62], Sordi et 
al., have reported that the release of several chemokines by damaged 
pancreatic islets attracted human MSCs expressing several chemokine 
receptors [63]; once MSCs have been transplanted, they migrate to 
pancreatic islets where they can be detected for up to several weeks 
later [63]. Interestingly, both Fiorina et al., and our group have shown 
murine MSC preferential migration to secondary lymphoid organs, 
including pancreatic lymphoid nodes, thereby suggesting that such 
homing ability could be crucial in modulating an immune response 
[33,58]. Nevertheless, MSCs could also modulate autoimmunity from 
distant sites because it has been reported that MSCs embolised in the 
lungs improve myocardial infarction by releasing anti-inflammatory 
factors [64].
MSC Administration in Treating Diabetic Complications
Chronic hyperglycaemia in diabetic patients leads to various 
metabolic alterations, inducing several secondary complications 
which are responsible for major morbidity and mortality [3]. This has 
prompted investigators to analyse the effect of using MSCs on glycaemic 
control and to evaluate its therapeutic effects regarding to secondary 
complications such as microvascular complications, including 
nephropathy, retinopathy, and neuropathy and wound healing which 
have been the main targets for several types of therapy involving MSCs. 
MSC-related therapy for diabetic nephropathy  
Diabetic nephropathy (DN) is now the most common cause of 
end-stage renal failure in Western countries and the major cause of 
mortality in T1DM patients [65,66]. It is a multifactorial and multistage 
disease which is characterised by a progressive increase in albuminuria, 
hypertension and a decline in glomerular filtration rate [67]. It has 
been proposed that pathophysiological mechanisms act jointly in 
all renal compartments (tubulointerstitium, glomeruli and vessels), 
thereby leading to characteristic histological abnormalities, including 
mesangial cell proliferation and hypertrophy, thickening of glomerular 
basement membrane, podocyte loss and interstitial inflammation with 
fibrosis [68].
Different cells interact together to enable the kidneys to fulfil their 
physiological role; MSCs can differentiate, regenerate and/or protect 
mesangial cells [69], tubular epithelial cells [70,71], endothelial cells 
[72,73] and podocytes [74,75]. However, the diabetic microenvironment 
negatively influences MSC differentiation, proliferation, survival 
and homing, essentially through the effect of AGE accumulation and 
inflammatory mediators [76,77]. Although MSCs have been described 
as being renotrophic [78], engraftment frequency is scarce, suggesting 
that transplanted cells secrete paracrine molecules which could mediate 
kidney recovery [79,80].
Several pre-clinical studies using immune compromised NOD/
SCID mice or STZ-induced T1DM models have shown that injecting 
MSCs has reduced DN progression, shown by reduced albuminuria 
(functional marker) and improved renal histology (structural marker) 
[59,81-85]. Renoprotection has been achieved without hyperglycaemia 
normalisation in some of these studies, thereby inferring that the 
therapeutic effect involved the direct MSCs action on the kidneys 
[81,84]. Recent studies have tried to highlight the intrinsic mechanisms 
involved in MSC renoprotective potential; research to date has shown 
that these cells essentially act through regulating oxidative stress [86], 
protecting podocytes from injury [83,87] and reducing inflammation 
and fibrosis [84,88]. 
The available animal models’ major limitation is that they only 
mimic the earlier stages of DN; the impact of MSC administration 
on diabetic individuals exhibiting advanced signs of diabetic kidney 
disease thus remains unproven.
MSC-related therapy for diabetic retinopathy 
Diabetic retinopathy (DR) is the leading cause of irreversible vision 
loss in developed countries [89]. DR prevalence in T1DM patients in 
the Western world is around 28% [90] and increases dramatically with 
DM progression; hence, almost all T1DM patients will have a degree 
of DR after 20 years of DM evolution [91]. The earliest morphological 
change observed during the initial stages of DR is a reduced amount of 
pericytes in retinal capillaries [92]; this is followed by the formation of 
acellular-occluded capillaries, occasional micro-aneurysms, increased 
leukostasis and the thickening of the vascular basement membrane 
[93]. Such alterations progressively affect retinal microvessel 
integrity leading to increased vascular permeability and swelling 
(non-proliferative retinopathy). Further vessel deterioration during 
advanced stages of the disease results in poor blood flow and ischaemia, 
leading to the formation of new abnormal blood vessels, widespread 
haemorrhage and loss of vision (proliferative retinopathy) [94]. It has 
been well-documented that a hyperglycaemic state also affects the 
entire neurosensory retina, accelerates neuronal apoptosis and activates 
glial supporting cells, leading to reduced colour and contrast sensitivity 
during the early stages of the disease [95].
There is growing evidence that local inflammation and oxidative 
stress play pivotal roles during early and late stages of DR [96,97], thereby 
inducing pericyte and neuronal degeneration. MSCs could thus have a 
great impact on DR treatment since they can act as immunomodulatory 
agents and reactive oxygen species (ROS) scavengers [98]. Furthermore, 
due to striking similarities between MSCs and pericytes, MSCs might 
replace the latter, thereby compensating for pericyte loss [99]; Mendel et 
al., and Rajashekhar et al., have shown that adipose-derived MSCs intra-
vitreally injected into diabetic mice were able to migrate and integrate 
into the retinal vasculature, leading to microvascular stabilisation and a 
marked reduction in capillary dropout [100,101].  
Another study has shown that intravenous injection of human 
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adipose-derived MSCs into rats having established DR has led to 
improved blood retinal barrier integrity [102]; some donor cells 
differentiated into photoreceptor or astrocyte-like cells inside the retina 
of these rats [102]. A single intravitreal injection of placental-derived 
MSCs into diabetic rats has also resulted in a significant decrease in 
retinal cell apoptosis, such effect being related to increased intravitreal 
concentration of several neuroprotective growth factors [103].
The major limitation of available DN animal models is that they 
only mimic the earlier stages of DR (non-proliferative retinopathy) 
due to their reduced lifespan [104]; the impact of injecting MSCs into 
individuals exhibiting advanced signs of DR thus remains unverified.
MSC-related therapy for diabetic polyneuropathy  
Diabetic polyneuropathy (DPN) is a peripheral nervous system 
disorder affecting up to 60% of long-standing T1DM patients [105]; 
DPN patients have decreased quality of life due to chronic pain, loss of 
sensation in different parts of the body and chronic wounds leading to 
amputation [105]. The most relevant pathological findings concerning 
diabetic patients have included axonal atrophy, demyelination, and nerve 
fibre loss, reduced nerve blood flow and impaired nerve regeneration 
[106]. Several mechanisms have currently been proposed for linking 
chronic hyperglycaemia to DPN [107]; one of the main factors is the 
production of oxidative stress due to altered glucose metabolism. ROS 
accumulation increases lipid peroxidation, induces DNA and protein 
damage, induces cellular apoptosis and reduces nerve blood flow [108]; 
ROS accumulation also leads to increased expression of several genes 
involved in inflammatory reactions and neuronal dysfunction [109]. 
MSCs could thus represent an excellent therapeutic option due to their 
ability to act as ROS scavenger and secrete several anti-inflammatory, 
neurotrophic and vasculogenic factors which could promote neuron 
survival and the repair of damaged nerves [18,110].
Two recent studies have shown that the injection of bone marrow-
derived MSCs into diabetic mice’s hind limb muscles has increased 
several neurotrophic factor expression levels and ameliorated nerve 
conduction deficit [111,112]. Transplanted cells were located around 
the vasa nervorum in these studies and improved its vascularity. Shibata 
et al., have shown that intramuscular MSC injection into diabetic mice 
has led to the production of pro-angiogenic factors (bFGF and VEGF) 
and this was associated with an increased ratio between capillaries 
and muscular fibres, followed by increased blood flow to the nerves, 
improved motor nerve conduction speed and reduced hyperalgesia 
[113]. To our knowledge, there have been no reports showing MSC 
differentiation into neural cells in diabetic mice, suggesting the secretion 
of neurotrophic and pro-angiogenic factors as the main mechanisms 
associated with such potential therapeutic effect.
MSC-related therapy for diabetic wounds
Chronic skin ulcers represent one of the most serious pathological 
consequences of diabetes; they are characterised by a loss of epidermal 
and dermal tissue [114]. About 10% to 25% of T1DM patients develop 
diabetic foot ulcers during their lifetime, representing a major factor 
contributing to amputation in these patients [115]. 
Around 50% of diabetic wounds are resistant to current therapies, 
even including the best available treatment involving chemicals, 
dressings and skin grafts [116]. Diabetic wound healing deficiency can 
be attributed to critical factors such as reduced peripheral blood flow 
and impaired growth factors and cytokine release by local fibroblasts 
and inflammatory cells, leading to a reduction in angiogenesis [117]. 
MSCs have been used to date in treating different skin disorders 
[20,118,119]; several groups have reported successful wound healing 
in pre-clinical models of diabetic wounds after the administration 
of autologous or allogeneic MSCs from different sources [120-123]. 
Wounds treated with MSCs in these reports have shown a qualitative 
improvement regarding histological characteristics, such as superior 
rete ridge architecture, multi-layered structure, improved dermal-
epidermal junction and the formation of new skin appendage structures, 
such as hair follicles and sebaceous glands [120-123]. 
Although the mechanisms by which MSCs ameliorate skin damage 
have been the subject of debate for years, two theories currently offer 
explanations for these cells’ therapeutic effects: bioactive soluble 
factor production (growth factors, cytokines and specific proteins) 
or their differentiation into dermal and epidermal cells [124,125]. 
Nevertheless, most studies agree that although MSCs can migrate to 
injury sites in response to chemotactic signals in vivo [126,127], only 
a small percentage of engrafted MSCs actually become incorporated 
and survive within damaged tissue [128]. On the other hand, other 
studies have revealed that transplanted MSCs do not necessarily have 
to be in close proximity to damaged tissue to promote wound repair 
and functional recovery, thereby suggesting that paracrine factor 
secretion is the main MSC therapeutic action concerned in repairing 
skin disorders [129,130]. This theory has been further reinforced by 
recent studies which have shown that allogeneic MSCs-conditioned 
medium has enhanced healing when administered locally into wounds 
[121,122,131-134].
Antibody-based protein array assays have shown that MSCs-
conditioned medium contains most of the 79 human cytokines. 
Successful wound healing is particularly related to the secretion of 
trophic factors, such as VEGF, IGF-1, bFGF, PDGF-BB, Ang-1, SDF-
1, EGF, KGF and MMP9, or cytokines, such as TGF-β, IL6 and IL8. 
These could contribute towards wound repair and skin regeneration by 
suppressing inflammation, angiogenesis and stimulating skin stem cell 
proliferation and differentiation into new keratinocytes [123,131,135-
138].  
Mscs: From Preclinical Data to Clinical Practice
Despite the large amount of preclinical data supporting a 
therapeutic role for MSCs in β-cell mass regeneration and treating 
diabetic complications, few clinical trials have involved using MSCs in 
T1DM patients. In one such trial, Haller et al. studied the safety and 
efficacy of MSC-containing autologous cord blood infusion concerning 
DM in children. This trial recruited T1DM patients shortly after the 
onset of disease whose autologous cord blood was stored in private 
banks. There were no significant adverse effects, suggesting that cord 
blood infusion was feasible and safe in the aforementioned conditions 
[139]. The patients treated had increased peripheral regulatory T-cell 
level and reduced insulin requirement six months after cord blood 
infusion, compared to children who just received insulin therapy 
[139]. Nevertheless, the therapeutic effect disappeared two years after 
cell infusion; no patient thus achieve long-term preservation of the 
remaining β-cell mass [140]. 
The concept of immunomodulation by cord blood-derived 
MSCs was recently taken up by Zhao et al., who developed a novel 
process for re-educating patients’ lymphocytes through co-culturing 
with allogeneic MSCs [141]. This device consisted of a stack of Petri 
dishes containing cord blood-derived MSCs functioning as part of a 
closed-loop system that circulates the patient’s blood through a blood 
cell separator, briefly co-cultured a patient’s lymphocytes with MSCs 
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in vitro and returned the lymphocytes to the patient’s circulation. In 
this setting, through secreted and cell-surface signalling molecules, 
the MSCs educated the lymphocytes passing through the device. 
Results from this trial highlighted the fact that such treatment led to a 
clinically-relevant improvement in T1DM patient’s metabolic control 
(increased C peptide levels and reduced daily insulin requirement in 
T1DM patients having or lacking residual β-cell mass), which lasted 
for months following a single treatment [141]. However, post-treatment 
observations regarding a larger number of patients covering a longer 
period of time are needed for evaluating whether the aforementioned 
therapeutic effects could be maintained for a longer period than that 
involved in the aforementioned study.
Hu et al. reported the results of a randomised controlled trial in 
another study aiming to evaluate the long-term effects of injecting 
Wharton’s jelly-derived MSCs for new-onset T1DM patients. Treated 
T1DM patients had better glycaemic control and increased C peptide 
levels after two years’ follow-up compared to individuals having the 
same age, diabetes’ duration and receiving intensive insulin therapy 
[142]. A few more trials involving the administration of MSCs to 
T1DM patients to induce β-cell mass regeneration are ongoing. One 
of them has involved the use of allogeneic bone marrow-derived MSCs 
(Prochymal, a commercial formulation consisting of human MSCs 
harvested from healthy volunteer donors) for determining whether 
MSCs could halt autoimmunity progression and restore glycaemic 
control in newly-diagnosed T1DM patients (NCT00690066) whilst 
other studies have involved recruiting T1DM patients for evaluating 
the efficacy of transplanting autologous bone marrow-derived MSCs 
(NCT01157403 and NCT02057211) or autologous adipose-derived 
MSCs (NCT00703599). Regarding diabetic complications, one 
recruiting clinical trial is actively investigating MSC safety and efficacy 
in diabetic nephropathy (IRCT201111291414N28) and, concerning 
diabetic wounds, two studies have been completed with bone marrow-
derived MSCs regarding ulcers in diabetic patients suffering critical 
limb ischemia (NCT00955669 and NCT01065337) whilst other is 
ongoing regarding umbilical cord-derived MSCs for diabetic foot 
(NCT01216865).
Our group considers that the paucity of clinical trials carried 
out to date has been related to remaining concerns regarding cell 
 
Figure 1: 3RWHQWLDOUROHRI06&VLQWKHUHJHQHUDWLRQRISDQFUHDWLFȕFHOOPDVVDQGLQFRQWUROOLQJGLDEHWLFPLFURYDVFXODUFRPSOLFDWLRQV
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therapy strategies which still need to be addressed. The effectiveness 
of a patient’s own cells needs to be evaluated, considering that MSCs 
derived from diabetic subjects may have reduced therapeutic potential 
[77]; experiments involving the use of autologous cells are necessary 
for addressing this concern. Cell therapy’s long-term effects must be 
tested; given that T1DM and diabetic complications progress over 
a long period of time, a single administration of MSCs may not be 
enough to maintain any therapeutic effect over a long period of time. 
Furthermore, since stem cells are being used on human patients, safety 
is an especially relevant concern regarding tumour induction through 
spontaneous malignant transformation of MSCs or by promoting 
tumour development and growth. Compared to other types of stem 
cell (embryonic stem cells or induced pluripotent stem cells), MSCs 
have a better biosafety profile and lower risk of tumorigenicity [143]. 
Cultured MSCs have usually shown progressive senescence and growth 
arrest without tumour formation [144]; however, such cells may still 
acquire genetic abnormalities and become tumorigenic in vivo due 
to the many rounds of replication which they undergo before being 
transplanted into patients [145]. In this sense, Jeong et al. found that 
the transplantation of bone marrow-derived MSCs into STZ-induced 
diabetic mice frequently induced tumour formation at the injection site 
[146]. One way of circumventing this problem has been to encapsulate 
cells within a barrier allowing the diffusion of nutrients but not 
larger molecules, antibodies or cells; encapsulation can be configured 
using many different polymers, methods and sizes [147] and has the 
theoretical advantage of protecting cells from an immune attack but 
also avoiding the dissemination of potentially-oncogenic derivatives.  
A better understanding of therapeutic mechanisms and careful 
assessment of the efficacy of clinical trials are also needed. 
Conclusion
MSCs have been shown to have the potential for revolutionising 
the treatment of many chronic diseases, including T1DM and its 
main complications. Progress made to date in understanding normal 
pancreas development has been crucial in formulating protocols aimed 
at directing MSC differentiation into insulin-producing cells in vitro. 
However, the feasibility and scalability of such attempts for achieving 
the final goal of large-scale β-cell replacement are still questionable; 
even with an abundant supply of MSCs-derived β-cells these will likely 
be targets for persistent autoimmune response in T1DM patients. Any 
efforts at replacing β-cells will thus require an additional approach 
for dealing with recurrent autoimmunity. MSC immunomodulatory 
properties are thus very useful since they could reduce self-reactive 
lymphocytes causing inflammatory damage to newly-formed β-cells. 
MSC ability to secrete trophic and angiogenic factors may also restrict 
islet damage by establishing a microenvironment which stimulates 
β-cell growth, survival and differentiation (Figure 1).
MSCs’ beneficial roles could also be very useful in treating the main 
T1DM-associated complications where the reduction of parenchymal 
cells, inflammation and changes in the microenvironment are the main 
effectors concerning tissue damage, thereby making MSCs an effective 
tool for the comprehensive treatment of diabetic patients (Figure 1).       
T1DM is undoubtedly a terrible, lifelong disease, involving 
substantial short-term and long-term complications. Insulin is fairly 
effective in combating it, albeit a cumbersome and imperfect therapy. 
Ongoing discussion thus concerns the level of risk doctors and patients 
are willing to accept in order to achieve a potential cure; it is expected 
that any new therapeutic approach (including cell therapy) must be 
associated with a low-risk profile, especially when being considered 
for use in children. Regarding such decision, further clinical trials will 
be critical for evaluating whether clinical benefits motivate the risk of 
assuming adverse effects and which patients would be most suitable for 
this kind of therapy. 
Even though considerable challenges lie ahead, ongoing advances 
in the field make an effective MSC-therapy for T1DM and its main 
complications a realistic goal for the near future.
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